Neurology
Breakthrough Alzheimer's Drug Slows Cognitive Decline by 35%
The FDA recently approved a new anti-amyloid antibody therapy that shows meaningful slowing of cognitive decline in early Alzheimer's patients in Phase 3 trials.
Understanding Amyloid and Tau
Alzheimer's disease is characterized by the accumulation of amyloid-beta plaques and tau tangles in the brain, disrupting neuronal communication. Anti-amyloid therapies like lecanemab (Leqembi) and donanemab use monoclonal antibodies to clear amyloid deposits, slowing the downstream cascade of neurodegeneration.
The CLARITY AD Trial
The Phase 3 CLARITY AD trial enrolled 1,795 participants with early Alzheimer's and found that lecanemab reduced cognitive decline by 27% on the CDR-SB scale over 18 months. Subsequent extension data and real-world observational studies suggest benefits persist with continued treatment.
Who Qualifies and What to Know
These therapies are approved for early-stage disease only - mild cognitive impairment or mild dementia with confirmed amyloid pathology via PET scan or CSF biomarkers. Amyloid-related imaging abnormalities (ARIA), a potentially serious side effect, require regular MRI monitoring. Genetic testing for APOE4 status is recommended before initiating treatment.
